Heather Preston MD joined Pivotal in 2018 and brings 30 years of healthcare experience. Most recently she was a Firm Partner and Managing Director at TPG Biotech and she is currently a Senior Advisor to TPG. Prior to joining TPG in 2005, Dr. Preston spent two years investing with JP Morgan Partners and she was also an Entrepreneur-in-Residence with New Enterprise Associates. Prior to becoming a venture capital investor, Heather spent five years at McKinsey & Co. in New York, where she was a leader of their pharmaceutical and medical products consulting practice. She advised large pharmaceutical companies and biotechnology companies on critical strategic issues such as R&D portfolio prioritization, M&A opportunities, new technology acquisitions, new product launches and product growth strategies.
Heather currently serves on the board of directors of Oxford Biomedica (LSE:OXB); Karuna Therapeutics (NASDAQ:KRTX); Entasis Therapeutics (NASDAQ:ETTX), Unchained Labs, Azura Opthalmics, Fusion Pharmaceuticals, Akouous and Avalyn Pharmaceuticals. She has previously served on multiple private and public boards including Albireo (NASDAQ:ALBO), Alder BioPharmaceuticals (NASDAQ:ALDR) (Acquired by Lundbeck in 2019), Aptalis Pharma (acquired by Forest Labs in 2014), and Elevation Pharmaceuticals (acquired by Sunovion in 2012). She was responsible for TPG Biotech’s investment in Par Pharmaceuticals (acquired by Endo Pharmaceuticals in 2015).
Heather has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. She completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospital, Harvard and sub-specialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award. Dr. Preston also serves on the Board of Trustees for the Harvard Discovery Council, the Fine Arts Museums of San Francisco, Saint Luke’s School and the Harlech Scholarship Foundation.
What is Heather Preston's net worth?
The estimated net worth of Heather Preston is at least $1.91 million as of September 4th, 2020. Dr. Preston owns 5,800 shares of Karuna Therapeutics stock worth more than $1,913,014 as of April 26th. This net worth evaluation does not reflect any other investments that Dr. Preston may own. Learn More about Heather Preston's net worth.
How do I contact Heather Preston?
Has Heather Preston been buying or selling shares of Karuna Therapeutics?
Heather Preston has not been actively trading shares of Karuna Therapeutics over the course of the past ninety days. Most recently, on Friday, September 4th, Heather Preston bought 350 shares of Karuna Therapeutics stock. The stock was acquired at an average cost of $72.36 per share, with a total value of $25,326.00. Following the completion of the transaction, the director now directly owns 5,800 shares of the company's stock, valued at $419,688. Learn More on Heather Preston's trading history.
Who are Karuna Therapeutics' active insiders?
Are insiders buying or selling shares of Karuna Therapeutics?
In the last twelve months, insiders at the sold shares 12 times. They sold a total of 89,119 shares worth more than $20,412,131.47. The most recent insider tranaction occured on March, 8th when insider Stephen K Brannan sold 5,000 shares worth more than $1,591,700.00. Insiders at Karuna Therapeutics own 13.2% of the company.
Learn More about insider trades at Karuna Therapeutics. Information on this page was last updated on 3/8/2024.
